Preclinical pharmacology of robenacoxib: A novel selective inhibitor of cyclooxygenase-2

Journal of Veterinary Pharmacology and Therapeutics

Volumn 32, Issue 1, 2009, Pages 1-17

  King, J N ^a   Dawson, J ^a   Esser, R E ^b   Fujimoto, R ^b   Kimble, E F ^b   Maniara, W ^b   Marshall, P J ^b   O'Byrne, L ^b   Quadros, E ^b   Toutain, P L ^c   Lees, P ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; ROBENACOXIB; UNCLASSIFIED DRUG; ZYMOSAN;

ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ENZYME INHIBITION; INTESTINE MUCOSA PERMEABILITY; KIDNEY FUNCTION; NONHUMAN; PAIN; PAW EDEMA; PHARMACODYNAMICS; PRIORITY JOURNAL; STOMACH ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CELL LINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; EDEMA; FEVER; HUMANS; ISOENZYMES; MALE; PAIN; PROTEIN BINDING; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

CANIS FAMILIARIS; RATTUS;

EID: 58449130096     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2008.00962.x     Document Type: Article

References (73)

1. Anderson, G.D., Hauser, S.D., McGarity, K.L., Bremer., M.E., Isakson, P.C. Gregory, S.A. (1996) Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. Journal of Clinical Investigation, 97, 2672 2679.
2. Appleton, I., Tomlinson, A., Mitchell, J.A. Willoughby, D.A. (1995) Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future anti-inflammatory therapy. Journal of Pathology, 176, 413 420.
3. Baraf, H.S.B., Fuentealba, C., Greenwald, M., Brzezicki, J., O'Brien, K., Soffer, B., Polis, A., Bird, S., Kaur, A. Curtis, S.P., for the EDGE Study Group (2007) Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. Journal of Rheumatology, 34, 408 420.
4. Bettini, R., Grossi, E., Rapazzini, P. Giardina, G. (1986) Diclofenac sodium versus acetylsalicylic acid: a randomized study in febrile patients. Journal of Internal Medicine Research, 14, 95 100.
5. Blobaum, A.L. Marnett, L.J. (2007) Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. Journal of Biology Chemistry, 282, 16379 16390.
6. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K. Schnitzer, T.J. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine, 343, 1520 1528.
7. Brune, K. Furst, D.E. (2007) Combining enzyme selectivity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability. Rheumatology, 46, 911 919.
8. Brune, K. Hinz, B. (2004) Selective cyclooxygenase-2 inhibitors: similarities and differences. Scandinavian Journal of Rheumatology, 33, 1 6.
9. Callan, O.H., So, O.Y. Swinney, D.C. (1996) The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. Journal of Biological Chemistry, 271, 3548 3554.
10. Capone, M.L., Tacconelli, S., Francesco, L.D., Sacchetti, A., Sciulli, M.G. Patrignani, P. (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins & other Lipid Mediators, 82, 85 94.
11. Chan, C.C., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Ford-Hutchinson, A.W., Forrest, M.J., Gauthier, J.Y., Gordon, R., Gresser, M., Guay, J., Kargman, S., Kennedy, B., Leblanc, Y., Leger, S., Mancini, J., O'Neill, G.P., Oullet, M., Patrick, D., Percival, M.D., Perrier, H., Prasit, P., Rodger, I., Tagari, P., Therien, M., Vickers, P., Visco, D., Wang, Z., Webb, J., Wong, E., Xu, L.-J., Young, R.N., Zamboni, R. Riendeau, D. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Journal of Pharmacology and Experimental Therapeutics, 290, 551 560.
12. Cheng, H.F. Harris, R.C. (2004) Cyclooxygenases, the kidney, and hypertension. Hypertension, 43, 525 530.
13. Chipkin, R.E., Latranyi, M.B., Iorio, L.C. Barnett, A. (1983) Determination of analgesic drug efficacies by modification of the Randall and Selitto rat yeast paw test. Journal of Pharmacological Methods, 10, 223 229.
14. Clarke, T.P. (2006) The clinical pharmacology of cyclooxygenase-2- selective and dual inhibitors. Veterinary Clinics of North America, 36, 1061 1085.
15. Cryer, B. Feldman, M. (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. American Journal of Medicine, 104, 413 421.
16. Dawson, J., Rordorf-Adam, C., Geiger, T., Towbin, H., Kunz, S., Nguyen, H., Zingel, O., Chaplin, D. Vosbeck, K. (1993) Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. I. Development and initial characterisation of the model. Agents and Actions, 38, 247 254.
17. Duncan, J.R., Prasse, J.R. Mahaffey, E.A. (1995) Veterinary Laboratory Medicine: Clinical Pathology, 3rd edn. Iowa State University press, Ames IA.
18. Esser, R., Berry, C., Du, Z., Dawson, J., Fox, A., Fujimoto, R.A., Haston, W., Kimble, E.F., Koehler, J., Peppard, J., Quadros, E., Quintavalla, J., Toscano, K., Urban, L., Van Duzer, J., Zhang, X., Zhou, S. Marshall, P.J. (2005a) Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. British Journal of Pharmacology, 144, 538 550.
19. Esser, R.E., Miserendino-Molteni, R., Sharr, M., Zhang, X., Porter, W., Ramos, L., Cramer, J.A., Zhuang, S., Georgieva, A. Maniara, W. (2005b) Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. European Journal of Pharmacological Sciences, 25, 25 30.
20. Farkouh, M., Kirshner, H., Harrington, R., Ruland, S., Verheugt, F., Schnitzer, T., Burmester, G., Mysler, E., Hochberg, M., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Gimona, A., Matchaba, P., Hawkey, C. Chesebro, J., on behalf of the TARGET Study Group 2004) Therapeutic Arthritis Research and Gastrointestinal Event Trial: a randomised controlled trial of lumiracoxib vs naproxen and ibuprofen: cardiovascular outcomes. The Lancet, 364, 675 684.
21. Flower, R.J. (2003) The development of COX2 inhibitors. Nature Reviews Drug Discovery, 2, 179 191.
22. Futaki, N., Yoshikawa, K., Hamasaka, Y., Arai, I., Higuchi, S., Iizuka, H. Otomo, S. (1993) NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. General Pharmacology, 24, 105 110.
23. Gierse, J.K., Koboldt, C.M., Walker, M.C., Seibert, K. Isakson, P.C. (1999) Kinetic basis for selective inhibition of cyclo-oxygenases. Biochemical Journal, 339, 607 614.
24. Gilroy, D.W., Tomlinson, A. Willoughby, D.A. (1998) Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. European Journal of Pharmacology, 355, 211 217.
25. Gilroy, D.W., Colville-Nash, P.R., Willis, D., Chivers, J., Paul-Clark, M.J. Willoughby, D.A. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nature Medicine, 5, 598 701.
26. Giraudel, J.M., Toutain, P.L. Lees, P. (2005) Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and application for predicting the selectivity of NSAIDs in the cat. American Journal Veterinary Research, 66, 700 709.
27. Hunt, R.H., Harper, S., Watson, D.J., Yu, C., Quan, H., Lee, M., Evans, J.K. Oxenius, B. (2003) The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. American Journal of Gastroenterology, 98, 1725 1733.
28. Jung, M., Lees, P., Seewald, W. King, J.N. (2009) Analytical determination and pharmacokinetics of robenacoxib in the dog. Journal of Veterinary Pharmacology and Therapeutics, 32, 41 48.
29. Kido, H., Murakami, N., Ito, A., Kimura, K., Kodera, N., Doi, T. Naruse, T. (1998) Anti-inflammatory, analgesic and anti-pyretic effects of d-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid (M-5011), a new non-steroidal anti-inflammatory drug, in rats and guinea pigs. Japanese Journal of Pharmacology, 76, 75 86.
30. Krausse, M.M., Brand, M.D., Krauss, S., Meisel, C., Vergin, H., Burmester, G.R. Buttgereit, F. (2003) Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis and Rheumatism, 48, 1438 1444.
31. Kujubu, D.A., Fletcher, B.S., Varnum, B.C., Lim, R.W. Herschman, H.R. (1991) TIS10, a phorbol ester tumorpromoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. Journal of Biological Chemistry, 266, 12866 12872.
32. Kulmacz, R.J. Lands, W.E. (1985) Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. Journal of Biological Chemistry, 260, 12572 12578.
33. Lees, P., Creed, R.F.S., Gerring, E.L., Gould, P.W., Humphreys, D.J., Maitho, T.E., Michell, A.R. Taylor, J.B. (1983) Biochemical and haematological effects of recommended dosage with phenylbutazone in horses. Equine Veterinary Journal, 15, 158 167.
34. Lees, P., Landoni, M.F., Giraudel, J. Toutain, P.L. (2004a) Pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs in species of veterinary interest. Journal of Veterinary Pharmacology and Therapeutics, 27, 479 490.
35. Lees, P., Giraudel, J., Landoni, M.F. Toutain, P.L. (2004b) PK-PD integration and PK-PD modeling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. Journal of Veterinary Pharmacology and Therapeutics, 27, 491 502.
36. Li, J.J., Norton, M.B., Reinhard, E.J., Anderson, G.D., Gregory, S.A., Isakson, P.C., Koboldt, C.M., Masferrer, J.L., Perkins, W.E., Seibert, K., Zhang, Y., Zweifel, B.S. Reitz, D.B. (1996) Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. Journal of Medicinal Chemistry, 39, 1846 1856.
37. Lichtenberger, L.M., Dial, E.J., Romero, J.J., Lechago, J., Jarboe, L.A. Wolfe, M.M. (1995) Role of luminal ammonia in the development of gastropathy and hypergastrinemia in the rat. Gastroenterology, 108, 320 329.
38. Mamdani, M., Juurlink, D.N., Lee, D.S., Rochon, P.A., Kopp, A., Naglie, G., Austin, P.C., Laupacis, A. Stukel, T.A. (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. The Lancet, 363, 1751 1756.
39. Mangold, J.B., Gu, H., Rodriguez, L.C., Bonner, J., Dickson, J. Rordorf, C. (2004) Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metabolism and Disposition, 32, 566 571.
40. Masferrer, J.L., Zweifel, B.S., Manning, P.T., Hauser, S.D., Leahy, K.M., Smith, W.G., Isakson, P.C. Seibert, K. (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proceedings of the National Academy of Sciences of the United States of America, 91, 3228 3232.
41. McCann, M.E., Andersen, D.R., Zhang, D., Brideau, C., Black, W.C., Hanson, P.D. Hickey, G.J. (2004) In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. American Journal of Veterinary Research, 65, 503 512.
42. Moore, N. (2007) Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clinical Drug Investigations, 27, 163 195.
43. Mukherjee, A., Hale, V.G., Borga, O. Stein, R. (1996) Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats. Inflammation Research, 45, 531 540.
44. Nakano, M., Denda, N., Matsumoto, M., Kawamura, M., Kawakubo, Y., Hatanaka, K., Hiramoto, Y., Sato, Y., Noshiro, M. Harada, Y. (2007) Interaction between cyclooxygenase (COX)-1- and COX-2 expression in the late phase of acute inflammation. European Journal of Pharmacology, 559, 210 218.
45. Pairet, M. Engelhardt, G. (1996) Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundamental Clinical Pharmacology, 10, 1 17.
46. Patrignani, P., Panara, M.R., Greco, A., Fusco, O., Natoll, C., Iacobelli, S., Cipollone, F., Ganci, A., Creminon, C. Maclouf, J. (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. Journal of Pharmacology and Experimental Therapeutics, 271, 1705 1712.
47. Pinheiro, R.M. Calixto, J.B. (2002) Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflammation Research, 51, 603 610.
48. Pollmeier, M., Toulemonde, C., Fleishmann, C. Hanson, P.D. (2006) Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Veterinary Record, 159, 547 551.
49. Randall, L.O. Selitto, J.J. (1957). A method for measurement of analgesic activity on inflamed tissue. Archives Internationale Pharmacodynamie, CXI, 409 419.
50. Renton, K.W. (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacology & Therapeutics, 92, 147 163.
51. Riendeau, D., Percival, M.D., Brideau, C., Charleson, S., Dube, D., Ethier, D., Falgueyret, J.P., Friesen, R.W., Gordon, R., Greig, G., Guay, J., Mancini, J., Ouellet, M., Wong, E., Xu, L., Boyce, S., Visco, D., Girard, Y., Prasit, P., Zamboni, R., Rodger, I.W., Gresser, M., Ford-Hutchinson, A.W., Young, R.N. Chan, C.C. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Journal of Pharmacology and Experimental Therapeutics, 296, 558 566.
52. Rordorf, C., Choi, L., Marshall, P. Mungold, J.B. (2005) Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clinical Pharmacokinetics, 44, 1247 1266.
53. Schnitzer, T., Burmester, G., Mysler, E., Hochberg, M., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., Gimona, A. Hawkey, C., on behalf of the TARGET Study Group 2004) Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) a randomised controlled trial of lumiracoxib vs naproxen and ibuprofen: reduction in ulcer complications. The Lancet, 364, 665 674.
54. Scott, G., Rordorf, C., Blood, P., Branson, J., Milosavlijev, S. Greig, G. (2002) Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Annals of Rheumatic Diseases, 61 (Suppl. 1 242.
55. Scott, G., Rordorf, C., Reynolds, C., Kalbag, J., Looby, M., Milosavljev, S., Weaver, M., Huff, J.P. Ruff, D.A. (2004) Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clinical Pharmacokinetics, 43, 467 478.
56. Sedgwick, A.D. Lees, P. (1986) Studies of eicosanoid production in the air pouch model of synovial inflammation. Agents and Actions, 18, 429 438.
57. Sedgwick, A.D., Sin, Y.M., Edwards, J.C. Willoughby, D.A. (1983) Increased inflammatory reactivity in newly formed lining tissue. Journal of Pathology, 141, 483 495.
58. Simon, L.S., Lanza, F.L., Lipsky, P.E., Hubbard, R.C., Talwalker, S., Schwartz, B.D., Isakson, P.C. Geis, G.S. (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis and Rheumatism, 41, 1591 1602.
59. Smale, S. Bjarnason, I. (2003) Determining small bowel integrity following drug treatment. British Journal of Clinical Pharmacology, 56, 284 291.
60. Smith, W.L. Langenbach, R. (2001) Why there are two cyclooxygenase isozymes. Journal of Clinical Investigation, 107, 1491 1495.
61. Smith, J.B. Willis, A.L. (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biology), 231, 235 237.
62. Smith, W.L., Dewitt, D.L. Garavito, R.M. (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annual Review of Biochemistry, 69, 145 182.
63. Talley, J.J., Brown, D.L., Carter, J.S., Graneto, M.J., Koboldt, C.M., Masferrer, J.L., Perkins, W.E., Rogers, R.S., Shaffer, A.F., Zhang, Y.Y., Zweifel, B.S. Seibert, K. (2000) 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzene- sulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. Journal of Medicinal Chemistry, 43, 775 777.
64. Taylor, J.B., Walland, A., Lees, P., Gerring, E.L., Maitho, T.E. Millar, J.D. (1983) Biochemical and haematological effects of a revised dosage schedule of phenylbutazone in horses. Veterinary Record, 112, 599 602.
65. Toutain, P.L. Bousquet-Melou, A. (2004) Plasma clearance. Journal of Veterinary Pharmacology and Therapeutics, 27, 415 425.
66. Vane, J.R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biology), 231, 232 235.
67. Wagner, J.G. (1967) Method of estimating relative absorption of a drug in a series of clinical studies in which blood levels are measured after single and/or multiple doses. Journal of Pharmaceutical Sciences, 72, 838 842.
68. Wallace, J.L., Chapman, K. McKnight, W. (1999) Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. British Journal of Pharmacology, 126, 1200 1204.
69. Warner, T.D., Giuliano, F., Vojnovi, I., Bukasa, A., Mitchell, J.A. Vane, J.R. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of Sciences of the United States of America, 96, 7563 7568.
70. Wennogle, L.P., Liang, H., Quintavalla, J.C., Bowen, B.R., Wasvary, J., Miller, D.B., Allentoff, A., Boyer, W., Kelly, M. Marshall, P. (1995) Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. FEBS Letters, 371, 315 320.
71. Willoughby, D.A., Moore, A.R., Colville-Nash, D.R. Gilroy, D. (2000) Resolution of inflammation. International Journal of Immunopharmacology, 22, 1131 1135.
72. Winter, C.A. Flataker, L. (1965) Reaction thresholds to pressure in edematous hindpaws of rats and responses to analgesic drugs. Journal of Pharmacology and Experimental Therapeutics, 150, 165 171.
73. Xie, W.L., Chipman, J.G., Robertson, D.S., Erikson, R.L. Simmons, D.L. (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proceedings of the National Academy of Sciences of the United States of America, 88, 2692 2696.